@unpublished{Bartfeld2016,
  author    = {Bartfeld, Sina},
  title     = {Modeling infectious diseases and host-microbe interactions in gastrointestinal organoids},
  series = {Developmental Biology},
  journal   = {Developmental Biology},
  issn      = {0012-1606},
  doi       = {http://dx.doi.org/10.1016/j.ydbio.2016.09.014},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-138788},
  year      = {2016},
  abstract  = {Advances in stem cell research have allowed the development of 3-dimensional (3D) primary cell cultures termed organoid cultures, as they closely mimic the in vivo organization of different cell lineages. Bridging the gap between 2-dimensional (2D) monotypic cancer cell lines and whole organisms, organoids are now widely applied to model development and disease. Organoids hold immense promise for addressing novel questions in host-microbe interactions, infectious diseases and the resulting inflammatory conditions. Researchers have started to use organoids for modeling infection with pathogens, such as Helicobacter pylori or Salmonella enteritica, gut- microbiota interactions and inflammatory bowel disease. Future studies will broaden the spectrum of microbes used and continue to establish organoids as a standard model for human host-microbial interactions. Moreover, they will increasingly exploit the unique advantages of organoids, for example to address patient-specific responses to microbes.},
  language  = {en}
}
@article{SchlagenhaufJakobEigenthaleretal.2016,
  author    = {Schlagenhauf, Ulrich and Jakob, Lena and Eigenthaler, Martin and Segerer, Sabine and Jockel-Schneider, Yvonne and Rehn, Monika},
  title     = {Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT},
  series = {Journal of Clinical Periodontology},
  volume    = {43},
  journal   = {Journal of Clinical Periodontology},
  number    = {11},
  doi       = {10.1111/jcpe.12606},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-186783},
  pages     = {948-954},
  year      = {2016},
  abstract  = {Aim: This randomized controlled trial assessed the impact of Lactobacillus reuteri on pregnancy gingivitis in healthy women. Materials and Methods: Forty-five healthy women (24 test/21 placebo) with pregnancy gingivitis in the third trimester of pregnancy were enrolled. At baseline Gingival Index (GI) and Plaque Index (PlI) were assessed at the Ramfjord teeth and venous blood taken for TNF-alpha analysis. Subsequently participants were randomly provided with lozenges to be consumed 2 9 daily until birth (approx. 7 weeks) containing >= 10(8) CFU L. reuteri ATCC PTA 5289 and >= 10(8) CFU L. reuteri DSM 17938 (test) or being devoid of L. reuteri (placebo). Within 2 days after birth recording of GI, PlI and blood sampling were repeated. Results: At baseline, mean GI and mean PlI did not differ significantly between both groups. In the test group mean TNF-alpha serum level was significantly (p < 0.02) lower than in the placebo group. At reevaluation, mean GI and mean PlI of the test group were both significantly (p < 0.0001) lower than in the placebo group. Mean TNF-alpha serum level did no longer differ significantly between the groups. Conclusions: The consumption of L. reuteri lozenges may be a useful adjunct in the control of pregnancy gingivitis.},
  language  = {en}
}